Open Access
Signal Transduction and Targeted Therapy, volume 6, issue 1, publication number 153
Extracellular matrix and its therapeutic potential for cancer treatment
Jiacheng Huang
1, 2, 3, 4, 5
,
Lele Zhang
1, 2, 3, 4, 5
,
Dalong Wan
1
,
Lin Zhou
1, 3, 4, 5
,
Shusen Zheng
1, 3, 4, 5
,
Shengzhang Lin
2, 6
,
Yiting Qiao
1, 3, 4, 5
3
NHC Key Laboratory of Combined Multi-Organ Transplantation, Hangzhou, China
|
5
Key Laboratory of Organ Transplantation, Hangzhou, China
|
6
Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China
|
Publication type: Journal Article
Publication date: 2021-04-23
scimago Q1
wos Q1
SJR: 8.737
CiteScore: 44.5
Impact factor: 40.8
ISSN: 20959907, 20593635
Cancer Research
Genetics
Abstract
The extracellular matrix (ECM) is one of the major components of tumors that plays multiple crucial roles, including mechanical support, modulation of the microenvironment, and a source of signaling molecules. The quantity and cross-linking status of ECM components are major factors determining tissue stiffness. During tumorigenesis, the interplay between cancer cells and the tumor microenvironment (TME) often results in the stiffness of the ECM, leading to aberrant mechanotransduction and further malignant transformation. Therefore, a comprehensive understanding of ECM dysregulation in the TME would contribute to the discovery of promising therapeutic targets for cancer treatment. Herein, we summarized the knowledge concerning the following: (1) major ECM constituents and their functions in both normal and malignant conditions; (2) the interplay between cancer cells and the ECM in the TME; (3) key receptors for mechanotransduction and their alteration during carcinogenesis; and (4) the current therapeutic strategies targeting aberrant ECM for cancer treatment.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.